

7. (Original) The method of claim 6 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered orally.


8. (Original) The method of claim 6 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered parenterally.

9. (Original) The method of claim 6 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered transdermally.

10. (Original) The method of claim 6 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered in a dosage of from about 0.01 μ g/day to about 100 μ g/day.

11. (Original) The method of claim 6 wherein said female human being is a post-menopausal female human being.

12. (Currently Amended) A method of inhibiting tumorigenesis in the treatment of a breast cancer comprising administering to a patient with a breast cancer an effective amount of 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ having the formula:



13. (Original) The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered orally.

14. (Original) The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered parenterally.

15. (Original) The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered transdermally.

16. (Original) The method of claim 12 wherein 2-methylene-19-nor-20(S)-1 α ,25-dihydroxyvitamin D₃ is administered in a dosage of from about 0.01 μ g/day to about 100 μ g/day.

17-22. (Canceled)